Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Docetaxel

- PMLiVE

Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments

MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain

- PMLiVE

AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer

The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

- PMLiVE

Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment

This is the first and only at-home subcutaneous treatment option for this disease

- PMLiVE

Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat

- PMLiVE

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

- PMLiVE

Roche and Nurix Therapeutics to partner in $2.3bn deal

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology

- PMLiVE

Roche opens new Swiss Institute of Human Biology research facility

The new building is part of a 1.5bn euro site investment

- PMLiVE

Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment

The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

- PMLiVE

Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer

The combination treatment showed a 35% reduction in the risk of disease progression

- PMLiVE

Lilly announces new study data on Inluriyo in metastatic breast cancer

The five-year survival rate for metastatic breast cancer is 30%

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links